| Patients, N | 29 |
| Median age, y (IQR, 25-75) | 52 (46-55) |
| Sex ratio M/F | 12/17 (0.7) |
| KPS | |
| Median at diagnosis: median (IQR, 25-75) | 80 (70-90) |
| Median before rdWBRT (IQR, 25-75) | 90 ([80-90) |
| Unifocal disease, n (%) | 9 (31) |
| Multifocal disease, n (%) | 20 (69) |
| Meningeal involvement, n | |
| Yes, n (%) | 6 (21%) |
| No | 18 |
| Unknown | 5 |
| Ophthalmic involvement, n | |
| Yes, n (%) | 4 (14%) |
| No | 22 |
| Unknown | 3 |
| Induction chemotherapy regimen, n | |
| R-MPV + R-A | 12 |
| R-MBVP + R-A | 10 |
| Other | 7 |
| Median HD-MTX infusions, n (IQR, 25%-75%) | 8 [6-8] |
| MTX dose >3 g/m2, n | |
| Yes | 25 |
| No | 2 |
| Unknown | 2 |
| Surgery (excluding biopsy), n | 0 |
| Neuropsychological follow-up, n (%) | 16 (55) |
| Early response to induction chemotherapy, n (%) | |
| CR/uCR | 7/4 (38) |
| PR | 18 (62) |
| Final response to induction chemotherapy, n (%) | |
| CR | 21 (72) |
| uCR | 8 (28) |
| Patients, N | 29 |
| Median age, y (IQR, 25-75) | 52 (46-55) |
| Sex ratio M/F | 12/17 (0.7) |
| KPS | |
| Median at diagnosis: median (IQR, 25-75) | 80 (70-90) |
| Median before rdWBRT (IQR, 25-75) | 90 ([80-90) |
| Unifocal disease, n (%) | 9 (31) |
| Multifocal disease, n (%) | 20 (69) |
| Meningeal involvement, n | |
| Yes, n (%) | 6 (21%) |
| No | 18 |
| Unknown | 5 |
| Ophthalmic involvement, n | |
| Yes, n (%) | 4 (14%) |
| No | 22 |
| Unknown | 3 |
| Induction chemotherapy regimen, n | |
| R-MPV + R-A | 12 |
| R-MBVP + R-A | 10 |
| Other | 7 |
| Median HD-MTX infusions, n (IQR, 25%-75%) | 8 [6-8] |
| MTX dose >3 g/m2, n | |
| Yes | 25 |
| No | 2 |
| Unknown | 2 |
| Surgery (excluding biopsy), n | 0 |
| Neuropsychological follow-up, n (%) | 16 (55) |
| Early response to induction chemotherapy, n (%) | |
| CR/uCR | 7/4 (38) |
| PR | 18 (62) |
| Final response to induction chemotherapy, n (%) | |
| CR | 21 (72) |
| uCR | 8 (28) |
PR, partial response; R-A, rituximab, cytarabine; R-MBVP, rituximab, methotrexate, BCNU, VP16, prednisone.